The EGFR and HER2 inhibitor TAK-788 has antitumor activity against non-small-cell lung cancer with EGFR exon 20 insertions, according to phase I/II findings reported at the 2019 ASCO Annual Meeting.
Phase I data indicate that the selective RET inhibitor BLU-667 elicits durable responses and is well tolerated by individuals with advanced non-small-cell lung cancer harboring a RET fusion.
Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.
Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer can achieve long-term survival with pembrolizumab monotherapy.
Lurbinectedin monotherapy is active in the second-line treatment of both platinum-sensitive and -resistant small-cell lung cancer, according to phase II results presented at the 2019 ASCO Annual Meeting.
Patients with treatment-naïve, nonmutated, nonsquamous, advanced non-small-cell lung cancer derive a significant survival benefit from the addition of the PD-L1 inhibitor atezolizumab to chemotherapy, indicate phase III trial findings.